Description: Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Home Page: www.compasstherapeutics.com
CMPX Technical Analysis
80 Guest Street
Boston,
MA
02135
United States
Phone:
617 500 8099
Officers
| Name | Title |
|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, CEO & Director |
| Dr. Vered Bisker-Leib MBA, Ph.D. | Pres & COO |
| Mr. Neil L. Lerner CPA | VP of Fin. |
| Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corp. Sec. |
| Anna Gifford | Communications Mang. |
| Dr. Peter F. Moesta Ph.D. | Interim Head of CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.684 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-04-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |